8th International Conference on Malignancies in AIDS and Other Immunodeficiencies
April 29-30, 2004
Main Auditorium, Natcher Conference Center
National Institutes of Health Campus, Bethesda, Maryland

Presented by the National Cancer Institute

Program

Thursday, April 29

8:00 AM – 6:00 PM Poster Presentations

8:30 AM Opening Remarks and Welcome
Jodi B. Black, Ph.D., Program Director, AIDS Malignancy Program, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH)

8:40 – Plenary Lectures
9:55 AM Moderator: Jodi B. Black, Ph.D., Program Director, AIDS Malignancy Program, DCTD, NCI, NIH

8:40 S1 Phase I Study of Interleukin-2 and Stem Cell Factor in Patients with AIDS or HIV and Cancer
   Michael Caligiuri, M.D., Director, Ohio State University Comprehensive Cancer Center

9:05 S2 NIH HIV Vaccine Initiatives
   Richard Koup, M.D., Senior Investigator and Chief, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH

9:30 S3 Immune Response to Viruses
   Louis Picker, M.D., Associate Director, Vaccine and Gene Therapy Institute, Director of the Vaccine Program, and Director, Pathobiology and Immunology Division, Oregon Health and Sciences University (OHSU)

9:55 AM Break

10:25 AM - 12:20 PM Human Papillomavirus (HPV) Immunology
Moderators: Joel Palefsky, F.R.C.P.(C), Director, Clinical Research Center, University of California, San Francisco (UCSF)
   T-C Wu, M.D., Ph.D., Associate Professor of Pathology, Oncology, Obstetrics and Gynecology and Molecular Microbiology and Immunology, The Johns Hopkins University (JHU)

10:25 S4 HPV Infection in the Context of Highly Active Antiretroviral Therapy (HAART)
   Joel Palefsky, M.D., F.R.C.P.(C), Director, Clinical Research Center, UCSF

10:45 S5 Development of HPV Human T Cell Mediated Assays
   Chien-Fu Hung, Ph.D., Assistant Professor of Pathology, JHU

11:05 S6 Overview and Challenges to Assessing T Cell Responses to HPV
   Malcolm John, M.D., M.P.H., Assistant Clinical Professor and Director, PositiveHealth Practice, UCSF
11:25  S7  Advances in the Immunology of HPV and the Continued Need for a Therapeutic HPV Vaccine
Martin Kast, Ph.D., Walter A. Richter Chair for Cancer Research, Norris Comprehensive Cancer
Center, University of Southern California (USC)

11:40  S8  Investigational HPV (Types 6, 11, 16, 18) L1 VLP Vaccine - Development Update
Eliav Barr, M.D., Senior Director, Biologics Clinical Research, Merck Research Laboratories

Noon  S9  Update on the Development of an HPV-16/18 Prophylactic Cervical Cancer Vaccine
Gary Dubin, M.D., Vice President, Worldwide STD Vaccine Development, Programs and Adult
Vaccine Franchise, GlaxoSmithKline Biologicals

12:20 PM  Lunch

1:30 -  2:30 PM  Abstract Presentations

Moderator: Doug Lowy, M.D., Laboratory Chief, Laboratory of Cellular Oncology, Center for Cancer
Research (CCR), NCI, NIH

1:30  1,2  Cancer Incidence and Survival Times Among Adults with AIDS in the Pre-HAART and HAART
Eras
Nancy Hessol, M.S.P.H., Assistant Adjunct Professor, UCSF

1:45  3  Assessment of HPV DNA Testing as an Adjunct to Primary Cervical Cytologic Screening in HIV+
Women
Tiffany Harris, Ph.D., Instructor, Department of Epidemiology and Population Health, Albert
Einstein College of Medicine

2:00  4  Artemisinin Is Cytotoxic for HPV-expressing Cervical Epithelial Cells but Not Primary Cervical
Cells
Astrid Baege, M.D., Research Fellow, CCR, NCI, NIH

2:15  5  A Novel Therapy for Cervical Cancer Using Spliceosome-mediated RNA Trans-splicing
Michael Patrick, B.S., Graduate Student, CCR, NCI, NIH

2:30 PM  Break

3:00-  4:00 PM  Immunology and Oncogenesis

Moderator: Cliona Rooney, Ph.D., Professor, Baylor College of Medicine

3:00  S10  Activation of CD21 and CD23 Gene Expression by Kaposi’s Sarcoma Herpesvirus (KSHV)
Replication and Transcription Activator (RTA)
Jae Jung, Ph.D., Professor of Microbiology and Molecular Genetics, Harvard Medical School

3:20  S11  Downregulation of MHC-I Molecules by Virally-encoded E3-ubiquitin Ligases
Laurent Coscoy, Ph.D., Assistant Professor of Immunology, University of California, Berkeley

3:40  S12  Improving Survival, Expansion and Persistence of Adoptively-transferred Tumor-specific CTLs
Cliona Rooney, Ph.D., Professor, Baylor College of Medicine

4:00 -  4:30 PM  Abstract Presentations

Moderator: Joseph Pagano, M.D., Professor of Medicine, University of North Carolina

4:00  6  The Mutator Pathway is a Feature of Immunodeficiency-related Lymphomas
Alex Duval, M.D., Ph.D., INSERM Institute

4:15  7  Expression of Activation Induced Cytidine Deaminase, Germinal Center B Cell Gene, Is Induced
by Infection with Epstein-Barr Virus (EBV)
Marta Epeldegui, Ph.D. Candidate, University of California, Los Angeles
Friday, April 30

8:00 AM - Poster Presentations
6:00 PM

8:30 AM Introductory Remarks
Ellen G. Feigal, M.D., Vice President of Clinical Sciences and Deputy Scientific Director, Translational Genomics Research Institute (TGen)

8:40 - 9:35 AM Plenary Lectures
Moderators: Ellen G. Feigal, M.D., Vice President of Clinical Sciences and Deputy Scientific Director, Translational Genomics Research Institute (TGen)
Michael Marco, International Program Coordinator, Adult AIDS Clinical Trials Group, Social and Scientific Systems

8:40 S13 Survey of Research in AIDS-Kaposi’s Sarcoma (KS) in Zimbabwe
Margaret Borok, M.D., Senior Lecturer, University of Zimbabwe College of Health Sciences

9:10 S14 Cervical Cancer Prevention - A Paradigm Shift?
Lynette Denny, M.B., Ch.B., M.M.E.D., Ph.D., F.C.O.G. (SA), Associate Professor and Senior Specialist, University of Cape Town, South Africa

9:35 - 10:35 AM Clinical Session: Bone Marrow Transplantation for AIDS-related Lymphoma
Moderators: David T. Scadden, M.D., Director, Hematologic Malignancies and Experimental Hematology and Co-Director, AIDS Research Center, Massachusetts General Hospital and Harvard Medical School
Lawrence Kaplan, Clinical Professor of Medicine, UCSF and Program Member, UCSF Comprehensive Cancer Center

David T. Scadden, M.D., Director, Hematologic Malignancies and Experimental Hematology and Co-Director, AIDS Research Center, Massachusetts General Hospital and Harvard Medical School

9:45 S16 Long Term Remission with Autologous Stem Cell Transplantation in High Risk HIV Associated Lymphoma
Amrta Y. Krishnan, M.D., Staff Physician, City of Hope Comprehensive Cancer Center

10:00 S17 High-dose Therapy Plus Autologous Hematopoietic Stem Cell Transplantation for HIV-related Lymphoma: Results and Impact on HIV Disease
Jean Gabarre, M.D., Hôpital Pitié-Salpêtrière, France

10:15 S10, 11 Clinical Outcome and Immunereconstitution in HIV-related Lymphomas After High Dose Therapy and Peripheral Blood Stem Transplantation
Cecilia Simonelli, M.D., Division of Medical Oncology A, National Cancer Institute, Aviano, Italy

10:25 Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:35 AM</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM - Noon</td>
<td>Abstract Presentations</td>
<td>Moderators: Elliott Kieff, M.D, Ph.D., Harriett Ryan Albee Professor of Microbiology and Molecular Genetics, Co-Director, Channing Laboratory, Harvard Medical School, and Senior Physician, Brigham and Women’s Hospital Alex M. Levine, M.D., Distinguished Professor of Medicine, Chief of Hematology, and Ronald H. Bloom Family Chair in Lymphoma, USC School of Medicine and Medical Director, Norris Cancer Hospital and Research Institute</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>12</td>
<td>Treatment of SCID Mice with a Statin Inhibits the Development of EBV-associated Lymphoma</td>
<td>Jeffrey Cohen, M.D., Jeffrey Cohen, M.D., Head of Medical Virology Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH</td>
</tr>
<tr>
<td>11:15</td>
<td>13</td>
<td>Antiviral Targeting of NF-κB and EBV Viral Latency in Burkitt Lymphoma</td>
<td>William Harrington, Jr., M.D., Assistant Professor of Hematology/Oncology, University of Miami School of Medicine</td>
</tr>
<tr>
<td>11:30</td>
<td>14</td>
<td>Liposome Encapsulated Doxorubicin (TLC D-99, Myocet™) with Cytoxan, Vincristine and Prednisone for AIDS-related Lymphoma: Therapy Results and Correlates of Response</td>
<td>Anil Tulpule, M.D., Assistant Professor of Medicine, USC and Norris Cancer Hospital and Research Institute</td>
</tr>
<tr>
<td>11:45</td>
<td>15</td>
<td>Phase I Trial of Antisense Oligo Against Vascular Endothelial Growth Factor (VEGF-AS, Veglin) in Relapsed and Refractory Malignancies</td>
<td>Alexandra M. Levine, M.D., Distinguished Professor of Medicine, Chief of Hematology, and Ronald H. Bloom Family Chair in Lymphoma, USC School of Medicine and Medical Director, Norris Cancer Hospital and Research Institute</td>
</tr>
<tr>
<td>Noon</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>Viral Load Assays: Utility and Issues</td>
<td>Moderator: Richard F. Ambinder, M.D., Ph.D., Director, Division of Hematologic Malignancies, JHU School of Medicine</td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>S18</td>
<td>Altered EBV Viral Setpoint Due to HIV-Related Immune Activation</td>
<td>Debbie van Baarle, Ph.D., Sanquin Blood Supply Foundation, The Netherlands</td>
</tr>
<tr>
<td>1:15</td>
<td>S19</td>
<td>Real Time Quantitative PCR Assays for Accurately Measuring Viral Load of HTLV, KSHV, EBV, HIV, HCV AND HBV: Uses and Potential Pitfalls</td>
<td>Denise Whitby, Ph.D., Head of Viral Epidemiology Section, AIDS Vaccine Program, NCI, NIH</td>
</tr>
<tr>
<td>1:30</td>
<td>S20</td>
<td>EBV AND KSHV Copy Number in Hodgkin’s Lymphoma and AIDS Lymphoma</td>
<td>Richard F. Ambinder, M.D., Ph.D., Director, Division of Hematologic Malignancies, JHU School of Medicine</td>
</tr>
<tr>
<td>1:45</td>
<td>Abstract Presentations</td>
<td>Moderator: Robert Yarchoan, M.D., Branch Chief, HIV &amp; AIDS Malignancy Branch, CCR, NCI, NIH</td>
<td></td>
</tr>
<tr>
<td>1:45</td>
<td>16</td>
<td>Flare of AIDS-associated KS Following HAART: A Manifestation of Immune Reconstitution Syndrome</td>
<td>David Aboulafia, M.D., Clinical Professor, University of Washington School of Medicine</td>
</tr>
<tr>
<td>2:00</td>
<td>17</td>
<td>Associations of Classic KS with Haplotypes of IL8, IL8RB, and IL13</td>
<td>Elizabeth E. Brown, M.P.H., Ph.D., Cancer Research Postdoctoral Fellow, NCI, NIH</td>
</tr>
</tbody>
</table>
2:15 18 KSHV Induced Angiogenesis and Differentiation to Lymphatic Endothelium  
Michael Lagunoff, Ph.D., Assistant Professor of Microbiology, University of Washington

2:30 PM Break

3:00 - Pathogenesis and Viral Oncology Session
4:00 PM  Moderator: Patrick Moore, M.D., M.P.H., Director, Molecular Virology Program, University of Pittsburgh Cancer Institute and Hillman Cancer Center

3:00 S21 Rethinking the Pathogenesis of KS  
Donald E. Ganem, M.D., Professor of Microbiology and Immunology, UCSF

3:20 S22 The Latency-associated Nuclear Antigen of KSHV Modulates Cellular Gene Expression and Protects Lymphoid Cells From p16ink4a-induced Cell Cycle Arrest  
Rolf Renne, Ph.D., Assistant Professor of Molecular Biology and Microbiology, Case Western Reserve University

3:40 S23 Tumorigenic Mechanisms of KSHV  
Ashlee Moses, Ph.D., Assistant Scientist, Vaccine and Gene Therapy Institute, OHSU

4:00 - Abstract Presentations  
5:00 PM  Moderator: Denise Whitby, Head of Viral Epidemiology Section, AIDS Vaccine Program, NCI, NIH

4:00 19 KSHV and RRV Capsid Structure at ≤10 Å Resolution and Identification of RRV- associated Proteins by Tandem Mass Spectrometry  
Christine M. O’Connor, B.S., Graduate Student, University of Virginia

4:15 20 LANA Mediated Intracellular Shuttling of KSHV Genomes  
Magdalena Weidner, B.S., Graduate Student, Kimmel Comprehensive Cancer Center, JHU

4:30 21 KSHV/HHV-8 Replication and Transcription Activator Regulated Both Viral and Cellular Genes by Binding to Interferon-Stimulated Response Element  
Luwen Zhang, Ph.D., Assistant Professor of Virology, University of Nebraska

4:45 22 A Second Self-reinforcing Loop Involving JUN/FOS, RTA, and RAP Drives KSHV Lytic Cycle Reactivation in PEL Cells at Earlier Stages than the C/EBPα, RTA, and RAP Loop  
Gary Hayward, M.D., Professor of Oncology, Pathology, Pharmacology, and Molecular Sciences, JHU School of Medicine

5:00 PM Adjourn to posters

Continuing Medical Education  
The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  

The NIH/FAES designates this education activity for a maximum of 13 hours in category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity. The CME form is available at the registration desk outside the main auditorium.

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health  
National Cancer Institute